ATE546132T1 - Prozess zur veränderung der kristallform von mycophenolat natrium salz - Google Patents

Prozess zur veränderung der kristallform von mycophenolat natrium salz

Info

Publication number: ATE546132T1
Authority: AT; Austria
Prior art keywords: changing; sodium salt; crystal form; mycophenolate sodium; mycophenolate
Prior art date: 2003-01-20

Application number

AT04703158T

Other languages

English (en)

Inventor

Sabine Pfeffer

Dierk Wieckhusen

Original Assignee

Novartis Ag

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-20

Filing date

2004-01-19

Publication date

2012-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE546132(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-01-19 Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE546132T1 publication Critical patent/ATE546132T1/de

Links

HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical class OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Furan Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

AT04703158T 2003-01-20 2004-01-19 Prozess zur veränderung der kristallform von mycophenolat natrium salz ATE546132T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0301259.8A GB0301259D0 (en)	2003-01-20	2003-01-20	Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en)	2003-01-20	2004-01-19	Process for modifying drug crystal formation

Publications (1)

Publication Number	Publication Date
ATE546132T1 true ATE546132T1 (de)	2012-03-15

Family

ID=9951448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04703158T ATE546132T1 (de)	2003-01-20	2004-01-19	Prozess zur veränderung der kristallform von mycophenolat natrium salz

Country Status (31)

Country	Link
US (3)	US20060122265A1 (de)
EP (2)	EP2308471A1 (de)
JP (1)	JP4549976B2 (de)
KR (5)	KR101129105B1 (de)
CN (2)	CN101333201A (de)
AR (2)	AR043343A1 (de)
AT (1)	ATE546132T1 (de)
AU (1)	AU2004206731B2 (de)
BR (1)	BRPI0406827A (de)
CA (2)	CA2706900A1 (de)
CL (1)	CL2004000073A1 (de)
CO (1)	CO5580738A2 (de)
CY (1)	CY1112772T1 (de)
DK (1)	DK1592401T3 (de)
EC (1)	ECSP055918A (de)
ES (1)	ES2382035T3 (de)
GB (1)	GB0301259D0 (de)
IL (1)	IL169484A (de)
MX (1)	MXPA05007691A (de)
MY (1)	MY148297A (de)
NO (1)	NO20053846L (de)
NZ (1)	NZ541073A (de)
PE (2)	PE20110276A1 (de)
PL (2)	PL376525A1 (de)
PT (1)	PT1592401E (de)
RU (1)	RU2388757C2 (de)
SG (1)	SG155046A1 (de)
SI (1)	SI1592401T1 (de)
TW (1)	TWI325785B (de)
WO (1)	WO2004064806A2 (de)
ZA (1)	ZA200504442B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0124953D0 (en)	2001-10-17	2001-12-05	Novartis Ag	Organic Compounds
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds
AR045957A1 (es) *	2003-10-03	2005-11-16	Novartis Ag	Composicion farmaceutica y combinacion
JP2007532585A (ja)	2004-04-26	2007-11-15	テバジョジセルジャールザ−トケルエンムケドレ−スベニュタ−ルシャシャ−グ	ミコフェノール酸及びそのエステル誘導体の調製方法
EP1740563A2 (de)	2004-04-27	2007-01-10	Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság	Mykophenolatmofetilverunreinigung
JP2008506784A (ja) *	2004-07-20	2008-03-06	テバジョジセルジャールザ−トケルエンムケドレ−スベニュタ−ルシャシャ−グ	結晶形ミコフェノール酸・ナトリウム
GB0419355D0 (en) *	2004-08-31	2004-09-29	Novartis Ag	Organic compounds
US20080176937A1 (en) *	2007-01-23	2008-07-24	Apotex Fermentation Inc.	Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
MX2011003731A (es) *	2008-10-09	2011-08-03	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Uso de solventes organicos en la granulacion humeda de moxifloxacino.
CN101756958B (zh) *	2008-11-10	2011-07-20	鲁南制药集团股份有限公司	一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
US8772512B2 (en) *	2009-07-10	2014-07-08	Janssen Pharmaceutica Nv	Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
WO2011046546A1 (en) *	2009-10-13	2011-04-21	Teva Pharmaceutical Industries Ltd.	Delayed release compositions
CN108558740B (zh)	2010-01-27	2021-10-19	艾尼纳制药公司	S1p1受体调节剂及其盐的制备方法
ES2596291T3 (es)	2010-05-11	2017-01-05	Janssen Pharmaceutica, N.V.	Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
CN103880799A (zh) *	2010-11-16	2014-06-25	北京京卫信康医药科技发展有限公司	麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) *	2010-11-16	2014-06-25	北京京卫信康医药科技发展有限公司	麦考酚酸钠的新晶型及其制备方法
CN103596944B (zh)	2011-04-13	2017-02-22	詹森药业有限公司	可用作sglt2的抑制剂的化合物的制备方法
TWI582078B (zh) *	2013-01-23	2017-05-11	北京貝美拓新藥研發有限公司	抑制脯氨酸羥化酶活性的化合物的晶型及其應用
HUE060476T2 (hu)	2015-06-22	2023-03-28	Arena Pharm Inc	(R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
LT3394051T (lt) *	2015-12-21	2020-08-10	Janssen Pharmaceutica N.V.	Kristalizacijos procedūra, skirta kanagliflozino hemihidrato kristalų gavimui
CN110545848A (zh)	2017-02-16	2019-12-06	艾尼纳制药公司	用于治疗具有肠外表现的炎症性肠病的化合物和方法
WO2018151873A1 (en)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of primary biliary cholangitis
CN108727317A (zh) *	2017-04-25	2018-11-02	鲁南制药集团股份有限公司	一种麦考酚酸的晶型物
CN108727318A (zh) *	2017-04-25	2018-11-02	鲁南制药集团股份有限公司	麦考酚酸的晶型物
US12156866B2 (en)	2018-06-06	2024-12-03	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
CN110922371B (zh) *	2019-12-27	2020-08-11	广东蓝宝制药有限公司	一种m2晶型麦考酚钠的制备方法
WO2021234544A1 (en)	2020-05-18	2021-11-25	Novartis Ag	Crystalline form of lnp023
KR20250013155A (ko) *	2022-05-31	2025-01-31	혼슈우 카가쿠고교 가부시키가이샤	4,4'－비스(1,1－비스(4－히드록시－3－메틸페닐)에틸)비페닐의 결정 및 그의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US158835A (en) *		1875-01-19		Improvement in mortising-tools
GB935432A (en) *	1958-05-29	1963-08-28	Secr Aviation	Improvements in the manufacture of crystalline substances
US3183263A (en) *	1962-10-19	1965-05-11	Commercial Solvents Corp	Method for changing the crystal habit of mono-sodium glutamate
US3187039A (en) *	1962-10-19	1965-06-01	Commercial Solvents Corp	Method for changing the crystal habit of monosodium glutamate
US3352906A (en) *	1963-02-04	1967-11-14	Charles R Parkerson	Habit modification and preparation of single crystal triglycine sulfate
GB1157099A (en) *	1966-09-27	1969-07-02	Ici Ltd	Fermentation Process
GB1157100A (en) *	1966-09-27	1969-07-02	Ici Ltd	Pharmaceutical Compositions
US3770390A (en) *	1971-02-26	1973-11-06	Dow Chemical Co	Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) *	1980-04-21	1981-03-31	Allied Chemical Corporation	Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en)	1980-06-08	1983-11-30	Yeda Res & Dev	Resolution of amino acids
JPS5875194A (ja) *	1981-10-30	1983-05-06	株式会社日立製作所	マトリクス表示装置及び駆動方法
JPS59232916A (ja) *	1983-06-16	1984-12-27	Shiraishi Chuo Kenkyusho:Kk	針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en)	1985-11-12	1995-12-08	Yeda Res & Dev	Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja)	1987-12-25	1995-05-17	東レ株式会社	有機化合物結晶の製造方法
EP0582452B1 (de) *	1992-08-04	1998-10-14	Toda Kogyo Corp.	Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
PL178522B1 (pl)	1993-09-15	2000-05-31	Syntex Inc	Krystaliczny, bezwodny związek, mykofenolan mofetylu, kompozycja odpowiednia do sporządzania wodnego preparatu dożylnego, sposób wytwarzania kompozycji odpowiedniej do sporządzania preparatu dożylnego i zestaw użyteczny do sporządzania dożylnego preparatu
JPH09209297A (ja) *	1996-01-26	1997-08-12	Nippon Paper Ind Co Ltd	艶消し軽量塗工紙及びその製造方法
ID18663A (id)	1996-04-12	1998-04-30	Novartis Ag	Komposisi farmasi berlapis enterik
KR100491274B1 (ko) *	1996-04-12	2005-09-05	노파르티스 아게	미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) *	1998-06-24	2000-07-21	Sanofi Sa	Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en)	2003-01-20	2003-02-19	Novartis Ag	Organic compounds

2003
- 2003-01-20 GB GBGB0301259.8A patent/GB0301259D0/en not_active Ceased
2004
- 2004-01-19 CA CA2706900A patent/CA2706900A1/en not_active Abandoned
- 2004-01-19 PT PT04703158T patent/PT1592401E/pt unknown
- 2004-01-19 AT AT04703158T patent/ATE546132T1/de active
- 2004-01-19 CA CA2509796A patent/CA2509796C/en not_active Expired - Lifetime
- 2004-01-19 PL PL376525A patent/PL376525A1/pl not_active Application Discontinuation
- 2004-01-19 RU RU2005126328/04A patent/RU2388757C2/ru active
- 2004-01-19 SI SI200431859T patent/SI1592401T1/sl unknown
- 2004-01-19 WO PCT/EP2004/000354 patent/WO2004064806A2/en not_active Ceased
- 2004-01-19 PE PE2011000069A patent/PE20110276A1/es active IP Right Grant
- 2004-01-19 AR ARP040100142A patent/AR043343A1/es unknown
- 2004-01-19 KR KR1020097022061A patent/KR101129105B1/ko not_active Expired - Lifetime
- 2004-01-19 ES ES04703158T patent/ES2382035T3/es not_active Expired - Lifetime
- 2004-01-19 CN CNA2008101443548A patent/CN101333201A/zh active Pending
- 2004-01-19 KR KR1020107024515A patent/KR20100120321A/ko not_active Ceased
- 2004-01-19 US US10/541,504 patent/US20060122265A1/en not_active Abandoned
- 2004-01-19 KR KR1020097022060A patent/KR20090115821A/ko not_active Ceased
- 2004-01-19 EP EP10177718A patent/EP2308471A1/de not_active Withdrawn
- 2004-01-19 MY MYPI20040142A patent/MY148297A/en unknown
- 2004-01-19 DK DK04703158.8T patent/DK1592401T3/da active
- 2004-01-19 PL PL393385A patent/PL213192B1/pl unknown
- 2004-01-19 PE PE2004000074A patent/PE20040826A1/es not_active Application Discontinuation
- 2004-01-19 SG SG200700660-4A patent/SG155046A1/en unknown
- 2004-01-19 AU AU2004206731A patent/AU2004206731B2/en not_active Expired
- 2004-01-19 CN CN200480002455A patent/CN100595199C/zh not_active Expired - Lifetime
- 2004-01-19 NZ NZ541073A patent/NZ541073A/en not_active IP Right Cessation
- 2004-01-19 KR KR1020057013313A patent/KR100855149B1/ko not_active Expired - Lifetime
- 2004-01-19 KR KR1020077016703A patent/KR20070087181A/ko not_active Ceased
- 2004-01-19 BR BR0406827-0A patent/BRPI0406827A/pt not_active Application Discontinuation
- 2004-01-19 TW TW093101302A patent/TWI325785B/zh not_active IP Right Cessation
- 2004-01-19 MX MXPA05007691A patent/MXPA05007691A/es active IP Right Grant
- 2004-01-19 JP JP2005518641A patent/JP4549976B2/ja not_active Expired - Fee Related
- 2004-01-19 EP EP04703158A patent/EP1592401B1/de not_active Revoked
- 2004-01-20 CL CL200400073A patent/CL2004000073A1/es unknown
2005
- 2005-05-31 ZA ZA200504442A patent/ZA200504442B/en unknown
- 2005-06-30 IL IL169484A patent/IL169484A/en active IP Right Grant
- 2005-07-15 EC EC2005005918A patent/ECSP055918A/es unknown
- 2005-07-25 CO CO05072728A patent/CO5580738A2/es not_active Application Discontinuation
- 2005-08-16 NO NO20053846A patent/NO20053846L/no not_active Application Discontinuation
2008
- 2008-12-18 US US12/337,663 patent/US8008511B2/en not_active Expired - Lifetime
2011
- 2011-08-04 US US13/198,022 patent/US8124795B2/en not_active Expired - Lifetime
2012
- 2012-05-14 CY CY20121100450T patent/CY1112772T1/el unknown
2016
- 2016-02-15 AR ARP160100409A patent/AR103711A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
US8008511B2 (en)	2011-08-30
US8124795B2 (en)	2012-02-28
PE20040826A1 (es)	2004-12-23
AU2004206731B2 (en)	2008-03-20
AR103711A2 (es)	2017-05-31
PT1592401E (pt)	2012-05-10
KR20050096940A (ko)	2005-10-06
WO2004064806A2 (en)	2004-08-05
KR20090115898A (ko)	2009-11-09
SG155046A1 (en)	2009-09-30
CL2004000073A1 (es)	2005-01-14
BRPI0406827A (pt)	2005-12-27
NZ541073A (en)	2008-12-24
JP4549976B2 (ja)	2010-09-22
US20110288313A1 (en)	2011-11-24
AU2004206731A1 (en)	2004-08-05
US20090209639A1 (en)	2009-08-20
RU2388757C2 (ru)	2010-05-10
PL376525A1 (pl)	2006-01-09
AU2004206731A8 (en)	2004-08-05
ZA200504442B (en)	2006-02-22
ES2382035T3 (es)	2012-06-04
IL169484A0 (en)	2007-07-04
PE20110276A1 (es)	2011-05-27
ECSP055918A (es)	2005-11-22
CN101333201A (zh)	2008-12-31
CA2706900A1 (en)	2004-08-05
GB0301259D0 (en)	2003-02-19
RU2005126328A (ru)	2006-07-27
AR043343A1 (es)	2005-07-27
KR101129105B1 (ko)	2012-04-12
EP1592401B1 (de)	2012-02-22
PL393385A1 (pl)	2011-03-14
US20060122265A1 (en)	2006-06-08
MXPA05007691A (es)	2005-09-30
IL169484A (en)	2016-03-31
NO20053846L (no)	2005-08-16
JP2006515016A (ja)	2006-05-18
CO5580738A2 (es)	2005-11-30
PL213192B1 (pl)	2013-01-31
WO2004064806A3 (en)	2004-10-28
KR20090115821A (ko)	2009-11-06
CN100595199C (zh)	2010-03-24
TWI325785B (en)	2010-06-11
CA2509796C (en)	2010-09-14
KR20100120321A (ko)	2010-11-15
EP1592401A2 (de)	2005-11-09
CY1112772T1 (el)	2016-02-10
KR100855149B1 (ko)	2008-08-28
KR20070087181A (ko)	2007-08-27
EP2308471A1 (de)	2011-04-13
TW200505505A (en)	2005-02-16
CN1738605A (zh)	2006-02-22
MY148297A (en)	2013-03-29
HK1084874A1 (en)	2006-08-11
CA2509796A1 (en)	2004-08-05
SI1592401T1 (sl)	2012-05-31
DK1592401T3 (da)	2012-05-21

Publication	Publication Date	Title
ATE546132T1 (de)	2012-03-15	Prozess zur veränderung der kristallform von mycophenolat natrium salz
DE602004026576D1 (de)	2010-05-27	Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz
DE60336326D1 (de)	2011-04-21	Verfahren zur herstellung des calciumsalzes von rosuvastatin
DE602004026008D1 (de)	2010-04-29	Verfahren zur Herstellung von Flexodruckformen
DE502004001613D1 (de)	2006-11-09	Verfahren zur herstellung von polyamiden
DE602005019899D1 (de)	2010-04-22	System zur behandlung von ischämischem schlaganfall
IS7148A (is)	2004-02-11	Aðferðir til að framleiða kalsíumsaltform statína
DE60209704D1 (de)	2006-05-04	Neue kristallforme von azithromycin
DE602004001053D1 (de)	2006-07-20	Patrone zur Zubereitung von Getränken
DE60138099D1 (de)	2009-05-07	Verfahren zur herstellung von substituierten octanoyl-amiden
DE60234897D1 (de)	2010-02-11	Tintenzusatzmittel zur Verbesserung von Verzögerung der Tintentropfen
HRP20150163T1 (xx)	2015-03-27	Postupak za proizvodnju n-supstituiranih 2-cijanopirolidina
DE502004005626D1 (de)	2008-01-10	Verfahren zur herstellung von organoacylphosphiten
DE60313837D1 (de)	2007-06-28	Nichtionische Zusätze zur Kontrolle der Pfützenbildung von Tintenstrahldruckertinten
EP1523700A4 (de)	2008-07-09	Verfahren zur kompensation von geringem tonerverbrauch
DE60300252D1 (de)	2005-02-03	Verfahren zur industriellen Herstellung von 5-Amino-3-carboxymethyl-4-cyano-2-thiphencarboxydimethylester
DE60220554D1 (de)	2007-07-19	Mikrowelleninduzierter prozess zur herstellung von substituierten 4-vinylphenolen
DE60234275D1 (de)	2009-12-17	Verfahren zur herstellung von diglyceriden
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004014217D1 (de)	2008-07-17	Verfahren für die Wiedergewinnung von Land Vorvertiefung
DE50211253D1 (de)	2008-01-03	Verfahren zur Herstellung von Makrokapseln
DE60318444D1 (de)	2008-02-14	Verfahren zur herstellung von nevirapin
ATE332956T1 (de)	2006-08-15	Verfahren zur senkung der viskosität von weichspülern
FR2869030B1 (fr)	2006-11-10	Procede de production d'alpha-alumine particulaire
DE60336986D1 (de)	2011-06-16	Verfahren zur herstellung von biarylverbindungen